ISRCTN15019599已完成未知
CCP-Cancer UK: Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) – a prospective companion study for patients with cancer and COVID-19
Clatterbridge Cancer Centre NHS Foundation Trust0 个研究点目标入组 5,000 人开始时间: 2020年11月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Patients with proven COVID-19 and a diagnosis of cancer who are enrolled into any tier of the Principal CCP-UK protocol
排除标准
- •None in addition to those specified in the Principal CCP-UK protocol:
- •Exclusion criteria specified in CCP-UK Protocol:
- •1. Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen
- •2. Refusal by participant, parent or appropriate representative
研究者
相似试验
已完成
1 期
A Phase I/IIa trial of BT1718 in patients with advanced solid tumours.CancerISRCTN11160449Cancer Research UK66
进行中（未招募）
1 期
A Phase I/II trial of UCB4594 in participants with advanced cancerAdvanced solid tumoursCancerISRCTN26628699Cancer Research UK167
进行中（未招募）
不适用
A trial looking at a new drug called AG-014699 for breast and ovarian cancer in people with gene faultsadvanced or metastatic breast or ovarian carcinoma (proven carrier of a mutation in BRCA1 or 2 gene)EUCTR2006-002348-27-GBCancer Research UK
进行中（未招募）
不适用
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. - The TAILORx TrialEUCTR2007-003810-32-IEthe All-Ireland cooperative oncology research group (ICORG)10,000
进行中（未招募）
不适用
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. - The TAILORx TrialEUCTR2007-003810-32-GBthe All-Ireland cooperative oncology research group (ICORG)10,000